NCT00087867View on ClinicalTrials.gov

Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2004

Study Completion Date

September 30, 2005

Conditions
Multiple Myeloma
Interventions
DRUG

SCIO-469

two 30-mg capsules three times daily

DRUG

SCIO-469 and bortezomib

In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period

All Listed Sponsors
lead

Scios, Inc.

INDUSTRY

NCT00087867 - Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | Biotech Hunter | Biotech Hunter